AgingResearch.NewsJoin free

Nitrase Therapeutics

CompanyUnited States

Nitrase Therapeutics develops 3 assets, the furthest preclinical (NDC-0524 in dementia with Lewy bodies). Mostly antibody and small molecule acting on SNCA, proteostasis and GLOD4; based in the United States.

3
Assets
Furthest stage
Preclinical
0
Trials
0
Signals

Pipeline

3

  • NDC-0524

    Selectively binds nitrated alpha-synuclein while leaving normal protein intact to reduce the spread of pathology.

    Preclinical, Antibody, SNCA, Proteostasis, dementia with Lewy bodies, multiple system atrophy

  • Brain Shuttle-NDC-0524

    Stage not known

  • Synuclein Nitrase Inhibitor

    Inhibits Synuclein Nitrase to block production of pathogenic nitrated alpha-synuclein.

    Stage not known, Small molecule, GLOD4

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Similar companies6

Intelligence